Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with PARP Inhibitor in Patients with Advanced Ovarian Cancer

Trial Profile

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with PARP Inhibitor in Patients with Advanced Ovarian Cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etidaligide (Primary) ; Poly(ADP-ribose) polymerase inhibitors
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Onxeo SA
  • Most Recent Events

    • 04 Nov 2019 According to an Onxeo SA media release, the company has received a Notice of Allowance from the USPTO, granting the Company a new patent covering the combination of AsiDNA with any PARP inhibitor (PARPi) for cancer treatment, in the United States.This new patent, which expands the protection further supports the initiation of this new clinical study in the coming months that is designed to validate this very unique effect of AsiDNA on the acquired resistance to a PARPi.
    • 25 Jul 2019 According to an Onxeo SA media release. company plans to initiate this trial no later than in the first half of 2020.
    • 25 Oct 2018 According to an Onxeo SA media release, Onxeo plans to start this study as soon as H1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top